Meeting
2020 ASCO Virtual Scientific Program
A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.
Authors
Ravit Geva
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Ravit Geva , Corinne Maurice-Dror , Mor Tal Moskovitz , Eitan Ben-Ami , Ari Raphael , Ilana Lorber , Marcel Rozencweig , Talia Golan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03983954
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3160)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3160
Abstract #
TPS3160
Poster Bd #
224
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
First Author: Martin Gutierrez
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas.
First Author: Michael J. Overman
Poster
2021 ASCO Annual Meeting
Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.
First Author: Vivek Subbiah
Poster
2021 ASCO Annual Meeting
Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.
First Author: Hui Kong Gan